Carisma Therapeutics, Inc. - Common Stock (CARM)
Competitors to Carisma Therapeutics, Inc. - Common Stock (CARM)
Adaptimmune Therapeutics PLC ADAP -21.46%
Adaptimmune focuses on T-cell therapy, specifically SPEAR T-cell therapies targeting cancer. Though Adaptimmune specializes in a different area of immune cell therapies compared to Carisma's macrophage technologies, both companies are competing for a limited pool of investors and market recognition within the rapidly evolving immunotherapy landscape. Adaptimmune's established clinical trial results and collaborations offer a competitive edge over newer entrants like Carisma.
Agenus Inc. AGEN -6.88%
Agenus Inc. focuses on immuno-oncology therapies, similar to Carisma Therapeutics, which is also exploring engineered cell therapies for cancer treatment. Both companies are developing innovative approaches to harness the immune system against tumors. Agenus has a broader clinical pipeline and established partnerships with large pharmaceutical companies, which provides it a competitive edge in terms of funding and research capabilities.
Immunocore Holdings plc
Immunocore is focused on its proprietary T-cell receptor platform for creating T-cell engaging therapies, effectively competing with Carisma's macrophage-based immunotherapy approach. They have achieved several clinical milestones in oncology, which enhances their visibility and credibility in the market. Immunocore's established partnerships and early successes give them a significant competitive advantage in the race to provide novel treatments for cancer.
Poseida Therapeutics, Inc. PSTX +0.00
Poseida Therapeutics utilizes its proprietary genetic engineering platform to develop P-BCMA-101 for treating multiple myeloma, which directly competes with Carisma's CAR-Macrophage technology aimed at immunotherapy for cancer. Poseida has reported clinical successes and has garnered attention for its unique messaging and targeted therapies, giving them a competitive advantage in market presence and investor confidence.
Sorrento Therapeutics, Inc.
Sorrento Therapeutics is involved in developing antibody-drug conjugates and other immunotherapeutic strategies, placing it in competition with Carisma's efforts in engineered cell therapies for cancer treatment. Sorrento's extensive portfolio and collaborations allow for a diversified approach to cancer immunotherapy, which could place them in a better position in terms of technological development and scalability.